Attention-Deficit/Hyperactivity Disorder (ADHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Attention-Deficit/Hyperactivity Disorder (ADHD) Market Outlook
Thelansis’s “Attention-Deficit/Hyperactivity
Disorder (ADHD) Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Attention-Deficit/Hyperactivity Disorder (ADHD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Attention-Deficit/Hyperactivity
Disorder (ADHD) Overview
Attention-Deficit/Hyperactivity
Disorder (ADHD) is a neurodevelopmental disorder with pediatric and adult
significance, characterized by chronic inattentive, restless, and hyperactive
behavior that interferes with daily function and development. Symptoms
typically emerge by 12 years and tend to vary widely in their expression, with
some having trouble with concentration and organization only, whereas others
report widespread restlessness and impulsivity. ADHD is increasingly understood
as involving deficits in executive function—cognitive processes such as
planning, working memory, and self-regulation—which can impact academic
performance, workplace productivity, and interpersonal relationships. The
condition often co-occurs with other issues, such as mood disorders, sleep
disorders, and anxiety, and diagnosis is made based on a comprehensive
evaluation with consideration of behavioral history across multiple settings.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment